ArticleFrontiers in pharmacology2022

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

Shanliang Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.